TW200730190A - New combination to treat liver fibrosis - Google Patents

New combination to treat liver fibrosis

Info

Publication number
TW200730190A
TW200730190A TW095125044A TW95125044A TW200730190A TW 200730190 A TW200730190 A TW 200730190A TW 095125044 A TW095125044 A TW 095125044A TW 95125044 A TW95125044 A TW 95125044A TW 200730190 A TW200730190 A TW 200730190A
Authority
TW
Taiwan
Prior art keywords
liver fibrosis
new combination
treat liver
combination
relates
Prior art date
Application number
TW095125044A
Other languages
English (en)
Inventor
Gary Craig Burgess
Roger Kerry
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of TW200730190A publication Critical patent/TW200730190A/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW095125044A 2005-07-11 2006-07-10 New combination to treat liver fibrosis TW200730190A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69856105P 2005-07-11 2005-07-11

Publications (1)

Publication Number Publication Date
TW200730190A true TW200730190A (en) 2007-08-16

Family

ID=37434222

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095125044A TW200730190A (en) 2005-07-11 2006-07-10 New combination to treat liver fibrosis

Country Status (15)

Country Link
US (1) US20090214527A1 (zh)
EP (1) EP1904100A1 (zh)
JP (1) JP2007023030A (zh)
KR (1) KR20080017094A (zh)
CN (1) CN101217980A (zh)
AR (1) AR054828A1 (zh)
AU (1) AU2006267976B2 (zh)
BR (1) BRPI0613459A2 (zh)
CA (1) CA2614622A1 (zh)
IL (1) IL188397A0 (zh)
MX (1) MX2008000659A (zh)
RU (1) RU2008101383A (zh)
TW (1) TW200730190A (zh)
WO (1) WO2007007162A1 (zh)
ZA (1) ZA200800116B (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2177537T1 (sl) * 2004-01-09 2012-01-31 Pfizer Protitielesa proti MAdCAM
US20080070823A1 (en) * 2006-09-15 2008-03-20 Philip Gorlin Liquid Detergent Composition
ES2524021T3 (es) * 2006-12-06 2014-12-03 Conatus Pharmaceuticals, Inc. Formas cristalinas del ácido (3S)-3-[N-(N'-(2-terc-butilfenil)oxamil)alaninil]amino-5-(2',3',5',6'-tetrafluorofenoxi)-4-oxopentanoico
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
JP5996190B2 (ja) 2008-09-19 2016-09-21 ヘンリー フォード ヘルス システムHenry Ford Health System カルパイン阻害のための方法、系および組成物
WO2012021800A2 (en) * 2010-08-13 2012-02-16 Banyan Biomarkers Caspase inhibitors as therapeutics for neural and organ injury and imaging
EP3456711A4 (en) * 2016-05-11 2019-10-16 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. CASPASE INHIBITOR AND PHARMACEUTICAL COMPOSITION, USE AND THERAPEUTIC METHOD THEREFOR
AU2018300189A1 (en) 2017-07-14 2020-01-30 Pfizer, Inc. Antibodies to MAdCAM

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7090845B2 (en) * 1998-05-13 2006-08-15 Genentech, Inc. Diagnosis and treatment of hepatic disorders
US6197750B1 (en) * 1998-07-02 2001-03-06 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
WO2004081049A1 (en) * 2003-03-10 2004-09-23 Auckland Uniservices Limited Monoclonal antibodies that recognise mucosal addressin cell adhesion molecule-1 (madcam-1), soluble madcam-1 and uses thereof
SI2177537T1 (sl) * 2004-01-09 2012-01-31 Pfizer Protitielesa proti MAdCAM
ATE483732T1 (de) * 2005-07-08 2010-10-15 Pfizer Ltd Madcam-antikörper

Also Published As

Publication number Publication date
KR20080017094A (ko) 2008-02-25
JP2007023030A (ja) 2007-02-01
IL188397A0 (en) 2008-08-07
AR054828A1 (es) 2007-07-18
WO2007007162A1 (en) 2007-01-18
RU2008101383A (ru) 2009-07-20
EP1904100A1 (en) 2008-04-02
CA2614622A1 (en) 2007-01-18
CN101217980A (zh) 2008-07-09
AU2006267976B2 (en) 2009-12-24
MX2008000659A (es) 2008-03-13
US20090214527A1 (en) 2009-08-27
AU2006267976A1 (en) 2007-01-18
BRPI0613459A2 (pt) 2011-01-11
ZA200800116B (en) 2008-12-31

Similar Documents

Publication Publication Date Title
MX2010006738A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
MX2010006736A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
TW200716119A (en) A solid pharmaceutical dosage formulation
TW200730190A (en) New combination to treat liver fibrosis
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
MY198422A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
EP2056818A4 (en) COMPOSITIONS AND METHODS FOR NEUROPROTECTION
TW200719913A (en) Anti-madcam antibody compositions
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
MX2009008925A (es) Compuestos de la formula (i) como inhibidores de proteasa de serina.
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
EA200701820A1 (ru) Применение диосметиновых соединений при лечении и профилактике тромботических патологий
TW200736227A (en) New compounds III
PA8684501A1 (es) Formulaciones de estrogenos conjugados y bazedoxifeno
WO2007056142A3 (en) Methods of preventing the serotonin syndrome and compositions for use therefor
MX2010005012A (es) Composiciones para el tratamieno y prevencion de inflamacion de los parpados que comprenden un ingrediente osmoticamente activo y un vasocosntrictor.
TW200700071A (en) Novel use
EP2069377A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES AND SKIN FUNCTIONAL DISORDERS
WO2008048121A3 (en) Macrocyclic cysteine protease inhibitors and compositions thereof
WO2007044325A3 (en) Apoe4 domain interaction inhibitors and methods of use thereof
EA200970164A1 (ru) Ингибиторы каспазы на основе пиридазинонового каркаса
RS54140B1 (en) USE OF 24-ORDER
TW200716561A (en) P38 inhibitors and methods of use thereof
UA96269C2 (uk) Інгібітори цистеїнпротеази та їх терапевтичне застосування